|
GSK PLC on Thursday said the US Food & Drug Administration expanded the use of its cancer medicine Jemperli, also known as dostarlimab, when combined with chemotherapy. The London-based pharmaceutical company said the ‘approval now includes mismatch repair proficient/microsatellite stable tumours, which represent majority of endometrial cancer cases’. GSK said the approval is for all adults with primary advanced or recurrent endometrial cancer, a cancer that affects the uterus. GSK said it was the first and only immuno-oncology-based treatment to show an overall survival benefit, citing phase 3 trial data. At the 2.5-year landmark, 61% of patients in the Jemperli plus chemotherapy group compared to 49% in the chemotherapy group were alive. GSK shares closed 0.5% higher at 1,519.00 pence each on Thursday in London. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
